Novartis AG (NYSE:NVS)’s share price gapped up before the market opened on Friday . The stock had previously closed at $77.68, but opened at $78.27. Novartis AG shares last traded at $79.20, with a volume of 967,147 shares traded.

Several research firms recently weighed in on NVS. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novartis AG in a research report on Wednesday, July 13th. Bank of America Corp. restated a “hold” rating on shares of Novartis AG in a report on Tuesday, July 12th. Zacks Investment Research downgraded Novartis AG from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. Argus restated a “hold” rating on shares of Novartis AG in a report on Thursday, August 25th. Finally, TheStreet upgraded Novartis AG from a “hold” rating to a “buy” rating in a report on Friday, June 24th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $91.20.

The firm has a market capitalization of $189.02 billion and a PE ratio of 28.34. The firm’s 50 day moving average price is $81.72 and its 200 day moving average price is $77.68.

Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.05. The business had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. Equities research analysts forecast that Novartis AG will post $4.73 earnings per share for the current year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.